Original source text
Key Takeaways Inspire Medical is positioned for growth as Inspire V drives a major product transition.Inspire V cuts implant time by over 20%, while FDA approvals broaden patient eligibility.Coding uncertainty and WISeR delays may worsen in Q2 before easing in the second half of 2026. Inspire Medical Systems (INSP - Free Report) is well-positioned for solid growth over the next few quarters as it navigates a significant product transition.Shares of this Zacks Rank #3 (Hold) company have declined 44.1% in the year-to-date period compared with the industry’s 6.8% fall. However, the S&P 500 Index has increased 10% in the same timeframe.
Inspire Medical, a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, has a market capitalization of $1.46 billion.
The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 181.2%.
Image Source: Zacks Investment Research
Positive Factors Driving INSP’s ProspectsStrong Clinical Innovation & Growing Clinical Evidence: Inspire Medical continues to strengthen its leadership in hypoglossal nerve stimulation through product innovation and expanding clinical evidence. The Inspire V system remains a key growth driver, offering a simplified implant procedure by integrating the respiratory sensor within the neurostimulator while reducing implant time by more than 20% versus Inspire IV. Clinical studies have demonstrated superior respiratory sensing, improved sleep apnea outcomes and strong patient adherence.
The recently published PREDICTOR study suggests many patients may be screened without drug-induced sleep endoscopy (DISE), reducing diagnostic burden and time to treatment. Long-term data from the ADHERE registry and independent studies presented at SLEEP 2026 demonstrated sustained improvements in apnea severity, therapy adherence and cardiovascular outcomes, with Inspire patients showing lower risks of stroke, myocardial infarction, atrial fibrillation and hospitalization than CPAP-treated or untreated patients. Having treated more than 135,000 patients globally and supported by more than 385 peer-reviewed publications, Inspire Medical continues to strengthen physician confidence and long-term adoption.
Regulatory Expansion & Commercial Execution: Inspire Medical continues expanding its addressable market through regulatory approvals while strengthening commercial execution. Recent FDA approvals broadened patient eligibility by increasing the upper apnea-hypopnea index threshold, expanding BMI criteria and authorizing Inspire therapy for certain pediatric Down syndrome patients. The launch of Inspire V and new CMS HCPCS Level II C-codes has further supported adoption while improving facility reimbursement clarity. Management is also pursuing a dedicated CPT code expected to take effect in 2028, providing a long-term reimbursement solution. The company has optimized its sales organization by strategically consolidating territories while increasing field clinical representatives to achieve its targeted one-to-one ratio with territory managers. International momentum remains encouraging, with first-quarter 2026 international revenues increasing 16.5% year over year, reflecting growing physician awareness and market penetration despite reimbursement headwinds.
Disciplined Financial Execution & Investment in Growth: Inspire Medical delivered resilient financial performance while maintaining a disciplined investment strategy. Revenues increased 1.6% year over year, while the company improved adjusted operating margin through favorable product mix and higher adoption of Inspire V, generating stronger operating cash flow than the prior-year period. Management remains focused on investments that directly support long-term expansion, including reimbursement education, field reimbursement specialists, digital patient engagement tools, marketing effectiveness, operational efficiencies and next-generation product development. These initiatives will begin contributing more meaningfully during the second half of 2026 and accelerate further in 2027 as reimbursement challenges ease.
Key Challenges for INSP StockCoding & Reimbursement Uncertainty: The biggest near-term challenge remains coding and reimbursement uncertainty for Inspire V procedures. Differences in billing practices across Medicare and commercial insurers have slowed prior authorizations, reduced patient pipeline activity and delayed procedures. Although CMS introduced facility billing codes and management is working toward a dedicated CPT code expected in 2028, reimbursement uncertainty is expected to continue affecting procedure volumes until providers gain confidence in billing practices.
Coding and reimbursement disruption, along with the WISeR program, negatively impacted first-quarter 2026 revenues by approximately $20 million and could reduce full-year 2026 revenues by $120-$150 million. The company expects second-quarter revenue pressure to worsen with an estimated revenue headwind of $40-$50 million due to lower prior authorization activity during the first quarter, before improving gradually during the second half of 2026.
WISeR Program Disrupting Procedure Volumes: The rollout of the WISeR’s prior authorization program across six Medicare pilot states has created additional administrative hurdles for providers. AI-driven authorization requirements and varying state-specific workflows have delayed procedures and reduced Medicare volumes during the first quarter. While management expects providers to adapt over time, the program is likely to remain a short-term headwind before becoming less disruptive later in 2026.
GLP-1 Adoption & Competitive Pressure: Inspire Medical also faces emerging external headwinds. Management acknowledged that increasing use of GLP-1 weight-loss therapies may temporarily delay Inspire procedures as some patients pursue medical treatment first. Although GLP-1 therapies could ultimately expand the eligible patient population by helping patients meet BMI requirements, the near-term impact on procedure volumes remains uncertain. At the same time, competition in the hypoglossal nerve stimulation market is gradually increasing, adding another factor that could weigh on growth until reimbursement challenges subside.
Estimate TrendInspire Medical is witnessing a positive estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north 1 cent to $1.05 per share.
The Zacks Consensus Estimate for second-quarter 2026 revenues and loss per share is pegged at $194.8 million and 22 cents, respectively.
Stocks to ConsiderSome better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%.
West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.
Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.